Novartis and Mesoblast Remestemcel-L Collaboration
Filed with ASX · · 3 pages · English
Melbourne, Australia; November 20, and New York, USA; November 19, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), today announced that it has entered into an exclusive worldwide license and collaboration agreement with Novartis for the development, manufacture and commercialization of Mesoblast’s mesenchymal stromal cell (MSC) product remestemcel-L, with an initial focus on the development of the
In the deck
Earlier from Mesoblast
- First Quarter Results Presentation
- DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
- COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C
- MSB Wins Fierce Biotech Innovation Award for Remestemcel-L
- DSMB Recommends Continuation of Phase 3 COVID-19 Trial
Later from Mesoblast
- Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
- Mesoblast Phase 3 Chronic Heart Failure Results
- Trading halt
- Mesoblast Update on COVID-19 ARDS Trial
- Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast